1. Home
  2. SMBC vs DSGN Comparison

SMBC vs DSGN Comparison

Compare SMBC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Missouri Bancorp Inc.

SMBC

Southern Missouri Bancorp Inc.

HOLD

Current Price

$62.06

Market Cap

613.1M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.27

Market Cap

504.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMBC
DSGN
Founded
1887
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
613.1M
504.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SMBC
DSGN
Price
$62.06
$9.27
Analyst Decision
Hold
Buy
Analyst Count
4
3
Target Price
$63.63
$15.00
AVG Volume (30 Days)
46.6K
488.2K
Earning Date
01-26-2026
03-09-2026
Dividend Yield
1.62%
N/A
EPS Growth
25.22
N/A
EPS
5.46
N/A
Revenue
$178,892,000.00
N/A
Revenue This Year
$17.06
N/A
Revenue Next Year
$4.96
N/A
P/E Ratio
$11.28
N/A
Revenue Growth
10.39
N/A
52 Week Low
$45.10
$2.60
52 Week High
$63.54
$10.31

Technical Indicators

Market Signals
Indicator
SMBC
DSGN
Relative Strength Index (RSI) 59.17 50.94
Support Level $59.65 $9.01
Resistance Level $62.58 $10.01
Average True Range (ATR) 1.29 0.68
MACD 0.01 -0.05
Stochastic Oscillator 79.07 57.22

Price Performance

Historical Comparison
SMBC
DSGN

About SMBC Southern Missouri Bancorp Inc.

Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: